Key Drivers
- Strong Cash Flow
- Intangible Heavy
- Dividend Stretch
AIAI Summary
QGEN is now best viewed as a re-rating story driven by the abrupt 2026 guidance reset and rising dependence on QuantiFERON, meaning the key investment question is whether management can broaden growth fast enough to offset concentration risk before valuation and sentiment deteriorate further, even though strong margins and cash flow still provide a near-term cushion.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Intangible Heavy
- •Dividend Stretch
QGEN remains a highly profitable, cash-generative business with strong margins and liquidity, but rising leverage, heavy intangibles, and earnings/dividend quality concerns temper the appeal.
Price Behavior
Key Price Behavior Insights:
- •Downtrend intact
- •$33 support
- •Rebound resistance
QGEN has been in a steady downtrend over the last month, but the slide is starting to stabilize near $33 support; until it reclaims $34.50 and especially $38.00, the chart remains cautious.
The selloff slowed and price began stabilizing around the low-$33 area
Sentiment & News
Key News Insights:
- •Guidance reset
- •Sales weakness
- •Legal scrutiny
Qiagen's sharp 2026 guidance cut, despite solid profitability, has damaged investor confidence and triggered shareholder-law investigations amid weaker sales expectations.
The outlook downgrade is likely to pressure QGEN shares further until management restores confidence in growth and disclosure quality
Similar Companies in Healthcare
Other companies in the same sector with AI ratings